Generic peptide APIs for ANDA and regional filings
Drug substance for approved peptide NCEs—long GLP-1 analogs, somatostatin analogs and GnRH agonists—supplied with analytics suited to generic dossiers. Routes emphasize scalable SPPS or hybrid manufacturing and impurity control against patent-expired reference products.
5+
frequent generic targets
ANDA
dossier-oriented COA
>98%
purity target (typical spec band)
Impurity
fingerprint vs RLD
kg
annual demand (program-dependent)
Generic peptide landscape
Generic peptides differ from small molecules: higher molecular weight, complex impurity profiles and often lipid or PEG conjugation in the innovator product. Drug substance supply still centers on the linear or lipidated peptide chain per the filing strategy.
Dossiers require justified specifications, reference standard traceability and stability data. This page summarizes indicative attributes for commonly filed APIs—binding specs appear in the quality agreement.
Representative generic peptide APIs
Data as of Indicative list
Illustrative peptide drug substances often pursued post–patent expiry. Status and phase are market-dependent, not Solenyx pipeline claims.
| Code | Modality | Mechanism | Indication | Phase |
|---|---|---|---|---|
| Semaglutide | GLP-1 analog | GLP-1 receptor agonist | Type 2 diabetes, obesity | Marketed (innovator) |
| Liraglutide | GLP-1 analog (acylated) | GLP-1 receptor agonist | Type 2 diabetes | Marketed |
| Tirzepatide | Dual GIP/GLP-1 | Incretin co-agonist | Type 2 diabetes, obesity | Marketed |
| Octreotide | Somatostatin analog | SST receptor agonist | Acromegaly, NET | Marketed |
| Leuprolide | GnRH agonist | GnRH receptor agonist (downregulation) | Prostate cancer, endometriosis | Marketed |
Figures are indicative industry-typical values. Lot- and project-specific data appear on the quotation and certificate of analysis.
CMC focus by API type
GLP-1 analogs (31–39 aa)
Lipidation site, peptide content
Hybrids and side-chain attachment affect impurity map
Octreotide (8 aa, cyclic)
Disulfide, optical purity
Wrong disulfide pairs are key related substances
Leuprolide (9 aa)
Pyroglutamyl N-term, epimers
Chiral controls at Gly and D-residues
Tirzepatide
Dual lipidation, long SPPS
Segment condensation may appear at scale
Reference standard
Qualified against RLD or Ph. Eur./USP
Sponsor program owns RLD lot
Figures are indicative industry-typical values. Lot- and project-specific data appear on the quotation and certificate of analysis.
Filing strategy considerations
| Topic | Generic implication | Drug substance ask |
|---|---|---|
| RLD impurity profile | Not more than RLD thresholds (FDA) | Impurity fate and purge data |
| Peptide content | Label claim on DS | AAA release each batch |
| Salt / counter-ion | Match RLD or justify | Fixed in spec |
| Stability | 3-zone data for dossier | Commitment lots per ICH |
| Site change | Post-approval comparability | Prior GMP route lock |
Figures are indicative industry-typical values. Lot- and project-specific data appear on the quotation and certificate of analysis.
Dossier-oriented deliverables
- GMP drug substance per approved specification
- Method validation summaries available to sponsor
- Stability data for module 3
- Certificate of suitability to monograph where monograph exists
- DMF or ASMF letter of access
Frequently asked questions
Long GLP-1 APIs can be quoted under generic programs with GMP scope. Feasibility and impurity strategy are confirmed before campaign commitment.
Related
GMP Peptide API
GMP-manufactured peptide drug substance for clinical trials and commercial demand under a quality system aligned to ICH and regional GMP expectations. Scope is drug substance—synthesis, purification, isolation, release and stability—not discovery-grade custom work.
View detailsPeptide NCE / CMC Development
Process and analytical development that connects research synthesis to a repeatable drug substance story: route selection, impurity fate, specification rationale and stability—structured phase by phase from preclinical supply through commercial readiness.
View detailsCustom Peptide Synthesis
Solid-phase and solution synthesis of linear and modified peptides for discovery, assay development and lead optimization. Scale, purity tier and QC depth are matched to how the material will be used—not every program needs the same finishing step.
View detailsPeptide Modifications
Terminal caps, cyclization, stapling, PTMs, fluorescent and affinity tags, PEG/lipid appendages and unnatural backbones—installed during SPPS or in solution after the chain is built. Each class changes synthesis time, purification and how the product should be specified on the COA.
View detailsReady to specify this for your program?
Share sequence, scale and documentation needs. We reply with indicative specs and a project-specific quotation.